Cardiol Therapeutics Inc Class A has seen a notable decline this week amidst recent developments in their clinical trials and financial maneuvers.
Cardiol Therapeutics Inc Class A (CRDL.TO) concluded the trading session with a price of C$2.41, reflecting a decrease of 1.65% for the day and a notable decline of 9.47% over the past week. Despite these recent declines, the stock has shown a remarkable year-to-date increase of 75.74%.
Advertisement
Cardiol Therapeutics Inc Class A
CRDL.TO
CRDL.TO
Cardiol Therapeutics Inc Class A
WealthAwesomeMarket cap
$292.85M
52W high
$3.23
52W low
$1.23
1W change
-9.47%
Beta
0.61
Analyst Price Targets
Based on analyst covering CRDL · as of Sep 17, 2026
Wall Street analysts forecast CRDL stock price to rise 151.0% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$6.00
+151.0% Upside
Current Price
C$2.39
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on CRDL's historical volatility
30-Day Vol
72.2%
Annualized
90-Day Vol
62.9%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$2.88
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$2.56 | C$1.99 – C$3.28 |
| 60 trading days | C$2.71 | C$1.91 – C$3.86 |
| 90 trading days | C$2.88 | C$1.87 – C$4.43 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should consider the recent news regarding the company’s clinical trial advancements and financial strategies, which may influence future performance despite the current price volatility.
C$2.41 Closing Price
The stock is currently trading at 59% of its 52-week range of C$1.23 to C$3.23.
Bull case
The completion of the Phase III MAVERIC trial enrollment ahead of schedule and the trial's expansion could boost investor confidence in the effectiveness of CardiolRx™, potentially leading to positive outcomes for the company.
Bear case
The recent price drop and lower trading volumes compared to the 20-day average might suggest decreasing investor interest, raising concerns about the stock’s short-term stability.
Recent Price Action
Advertisement
This week, Cardiol Therapeutics Inc Class A stock closed at C$2.41, marking a 1D decline of 1.65% and a 1W drop of 9.47%. The stock has shown considerable volatility over the past month, with a decrease of 11.48%, although it remains significantly up 75.74% year-to-date.
Catalysts and Company News
Recent headlines highlight Cardiol Therapeutics' achievement in reaching its Phase III MAVERIC trial enrollment target ahead of schedule, as well as plans to expand the trial to further assess the efficacy of CardiolRx™. Additionally, the company secured over USD $7 million through the exercise of outstanding common share purchase warrants, enhancing its financial position ahead of pivotal trial data. These developments could be crucial for investors looking at the company's growth potential.
Technical Picture
From a technical standpoint, the stock is trading just above its 50-day moving average of C$2.39, which is up by 0.8% relative to the current price. The 200-day moving average stands at C$1.77, indicating a stronger performance over the longer term with a 36.2% increase compared to the current price. The stock's 52-week range is C$1.23 to C$3.23, placing it at 59% of its range. With a beta of 0.61, CRDL.TO exhibits lower volatility compared to the broader market. However, the recent trading volume of 118,185 shares is significantly below the 20-day average of 295,012 shares, suggesting reduced trading activity.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
